Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 116

1.

A polysome-based microRNA screen identifies miR-24-3p as a novel pro-migratory miRNA in mesothelioma.

Oliveto S, Alfieri R, Miluzio A, Scagliola A, Seclì RS, Gasparini P, Grosso S, Cascione L, Mutti L, Biffo S.

Cancer Res. 2018 Aug 2. pii: canres.0655.2018. doi: 10.1158/0008-5472.CAN-18-0655. [Epub ahead of print]

PMID:
30072395
2.

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R.

J Thorac Oncol. 2018 Sep;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011. Review.

PMID:
29966799
3.

Surgery for malignant pleural mesothelioma: an international guidelines review.

Ricciardi S, Cardillo G, Zirafa CC, Carleo F, Facciolo F, Fontanini G, Mutti L, Melfi F.

J Thorac Dis. 2018 Jan;10(Suppl 2):S285-S292. doi: 10.21037/jtd.2017.10.16. Review.

4.

Insight into glucocorticoid receptor signalling through interactome model analysis.

Bakker E, Tian K, Mutti L, Demonacos C, Schwartz JM, Krstic-Demonacos M.

PLoS Comput Biol. 2017 Nov 6;13(11):e1005825. doi: 10.1371/journal.pcbi.1005825. eCollection 2017 Nov.

5.

Giant atypical lipoma.

Mascarenhas MRM, Mutti LA, Paiva JMG, Enokihara MMSES, Rosa IP, Enokihara MY.

An Bras Dermatol. 2017 Jul-Aug;92(4):546-549. doi: 10.1590/abd1806-4841.20174447.

6.

Immunotherapy advances for mesothelioma treatment.

Bakker E, Guazzelli A, Ashtiani F, Demonacos C, Krstic-Demonacos M, Mutti L.

Expert Rev Anticancer Ther. 2017 Sep;17(9):799-814. doi: 10.1080/14737140.2017.1358091. Epub 2017 Jul 31. Review.

PMID:
28724330
7.

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.

Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L.

Expert Opin Investig Drugs. 2017 Aug;26(8):933-944. doi: 10.1080/13543784.2017.1351545. Epub 2017 Jul 12. Review.

PMID:
28679291
8.

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

PLoS One. 2017 Jun 22;12(6):e0180317. doi: 10.1371/journal.pone.0180317. eCollection 2017.

9.

Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.

De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S.

Sci Rep. 2017 Jun 9;7(1):3140. doi: 10.1038/s41598-017-02694-0.

10.

Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia.

Qattan MY, Bakker EY, Rajendran R, Chen DW, Saha V, Liu J, Zeef L, Schwartz JM, Mutti L, Demonacos C, Krstic-Demonacos M.

PLoS One. 2017 Jun 5;12(6):e0178606. doi: 10.1371/journal.pone.0178606. eCollection 2017.

11.

The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.

Pattarozzi A, Carra E, Favoni RE, Würth R, Marubbi D, Filiberti RA, Mutti L, Florio T, Barbieri F, Daga A.

Stem Cell Res Ther. 2017 May 25;8(1):119. doi: 10.1186/s13287-017-0573-7.

12.

Giant congenital melanocytic nevi: 40 years of experience with the serial excision technique.

Mutti LA, Mascarenhas MRM, Paiva JMG, Golcman R, Enokihara MY, Golcman B.

An Bras Dermatol. 2017 Mar-Apr;92(2):256-259. doi: 10.1590/abd1806-4841.20174885.

13.

Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.

Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddis R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S.

Genes Cancer. 2017 Jan;8(1-2):438-452. doi: 10.18632/genesandcancer.129.

14.
15.

Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.

De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellè L, Vodicka P, Mutti L, Foddis R, Cristaudo A, Gemignani F, Landi S.

Occup Environ Med. 2017 Jun;74(6):456-463. doi: 10.1136/oemed-2016-104024. Epub 2017 Mar 25.

PMID:
28343162
16.

Anti-CTLA-4 therapy for malignant mesothelioma.

Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L.

Immunotherapy. 2017 Mar;9(3):273-280. doi: 10.2217/imt-2016-0123. Review.

PMID:
28231719
17.

Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.

Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L.

Genes Cancer. 2016 Nov;7(11-12):340-354. doi: 10.18632/genesandcancer.124. Review.

18.

New standard for assessing asbestos exposure and its consequences?

Oliver LC, Welch L, Frank AL, Lemen RA, Mutti L.

Occup Environ Med. 2016 Oct;73(10):709-10. doi: 10.1136/oemed-2016-103693. Epub 2016 Jul 27. No abstract available.

PMID:
27466614
19.

Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.

Fiorillo M, Lamb R, Tanowitz HB, Mutti L, Krstic-Demonacos M, Cappello AR, Martinez-Outschoorn UE, Sotgia F, Lisanti MP.

Oncotarget. 2016 Jun 7;7(23):34084-99. doi: 10.18632/oncotarget.9122.

20.

A new species of Paraberrapex Jensen, 2001 (Cestoda: Lecanicephalidea) from Squatina guggenheim Marini (Squatiniformes: Squatinidae) off Argentina.

Mutti LD, Ivanov VA.

Folia Parasitol (Praha). 2016 Mar 8;63. pii: 2016.007. doi: 10.14411/fp.2016.007.

Supplemental Content

Loading ...
Support Center